Australia markets close in 1 hour 39 minutes

Ascendis Pharma A/S (ASND)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
134.00-3.20 (-2.33%)
At close: 04:00PM EDT
133.74 -0.26 (-0.19%)
After hours: 07:05PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 7.58B
Enterprise value 7.96B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)21.34
Price/book (mrq)N/A
Enterprise value/revenue 24.18
Enterprise value/EBITDA -21.93

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 341.15%
S&P500 52-week change 324.49%
52-week high 3161.00
52-week low 383.75
50-day moving average 3146.83
200-day moving average 3117.17

Share statistics

Avg vol (3-month) 3333.45k
Avg vol (10-day) 3308.35k
Shares outstanding 556.61M
Implied shares outstanding 658.01M
Float 856.43M
% held by insiders 10.76%
% held by institutions 1107.38%
Shares short (15 Apr 2024) 43.6M
Short ratio (15 Apr 2024) 411.55
Short % of float (15 Apr 2024) 49.16%
Short % of shares outstanding (15 Apr 2024) 46.36%
Shares short (prior month 15 Mar 2024) 42.94M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Currency in EUR.

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin -152.44%
Operating margin (ttm)-51.25%

Management effectiveness

Return on assets (ttm)-25.51%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)329.02M
Revenue per share (ttm)5.82
Quarterly revenue growth (yoy)185.50%
Gross profit (ttm)N/A
EBITDA -354.52M
Net income avi to common (ttm)-501.57M
Diluted EPS (ttm)-9.28
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)320.24M
Total cash per share (mrq)5.63
Total debt (mrq)669.01M
Total debt/equity (mrq)N/A
Current ratio (mrq)3.76
Book value per share (mrq)-4.19

Cash flow statement

Operating cash flow (ttm)-421.9M
Levered free cash flow (ttm)-357.18M